Perioperative dexmedetomidine significantly reduced the incidence of postoperative atrial fibrillation (OR 0.82) compared to controls in adult patients undergoing cardiac surgery.
Meta-Analysis (n=2,933)
Does perioperative dexmedetomidine reduce the incidence of postoperative atrial fibrillation in adult patients undergoing cardiac surgery?
Perioperative dexmedetomidine reduces the risk of postoperative atrial fibrillation in adult cardiac surgery patients, but does not significantly affect stroke, length of stay, or mortality.
Effect estimate: OR 0.82 (95% CI 0.69-0.98)
Absolute Event Rate: 20.38% vs 24.64%
p-value: p=.03
BACKGROUND: Postoperative atrial fibrillation is a common consequence of cardiac sur-gery with increased stroke complications and mortality. Although dexmedetomidine is thought to prevent postoperative atrial fibrillation and stroke because of its sympa-tholytic and anti-inflammatory properties, data from different studies show the effect of dexmedetomidine on postoperative atrial fibrillation and stroke uncertain in adult patients with cardiac surgery. METHODS: A database including EMBASE, PubMed, and Cochrane CENTRAL was searched for randomized controlled trials comparing dexmedetomidine with placebo or other anesthetic drugs in adult cardiac surgery. The primary outcome was the incidence of postoperative atrial fibrillation. The secondary outcomes were the incidence of postop-erative stroke, mechanical ventilation duration, intensive care unit length of stay, hospi-tal length of stay, and mortality. RESULTS: Eighteen trials with a total of 2933 patients were enrolled in the meta-analyses. Compared with controls, dexmedetomidine significantly reduced the incidence of post-operative atrial fibrillation odds ratio, 0.82; 95% CI, 0.69-0.98; P = .03. There was no sig-nificant difference between groups in stroke (odds ratio, 1.36; 95% CI, 0.59-3.16; P = .47), mechanical ventilation duration weighted mean difference, -0.17; 95% CI, -0.35 to 0.14;P=.39, intensive care unit length of stay (weighted mean difference, -0.03; 95% CI,-0.93 to 0.87; P = .95), hospital length of stay (weighted mean difference, -0.04; 95% CI,-0.40 to 0.32; P = .83) and mortality (odds ratio, 0.72; 95% CI, 0.32-1.60; P = .42). CONCLUSION: Perioperative dexmedetomidine reduced the incidence of postoperative atrial fibrillation in adult patients undergoing cardiac surgery. But there was no signifi-cant difference in the incidence of stroke, mechanical ventilation duration, intensive care unit length of stay, hospital length of stay, and mortality.
Jing et al. (2022) conducted a meta-analysis in Adult patients undergoing cardiac surgery (n=2,933). Dexmedetomidine vs. Placebo or other anesthetic drugs (propofol, morphine, remifentanil) was evaluated on Incidence of postoperative atrial fibrillation (OR 0.82, 95% CI 0.69-0.98, p=.03). Perioperative dexmedetomidine significantly reduced the incidence of postoperative atrial fibrillation (OR 0.82) compared to controls in adult patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: